Bendamustine

Generic Name
Bendamustine
Brand Names
Belrapzo, Bendeka, Treanda, Vivimusta
Drug Type
Small Molecule
Chemical Formula
C16H21Cl2N3O2
CAS Number
16506-27-7
Unique Ingredient Identifier
9266D9P3PQ
Background

Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophili...

Indication

Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Associated Conditions
Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma
Associated Therapies
-

Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma

Phase 1
Completed
Conditions
Interventions
First Posted Date
2013-06-10
Last Posted Date
2019-02-12
Lead Sponsor
Seagen Inc.
Target Recruit Count
55
Registration Number
NCT01874054
Locations
🇺🇸

University of Nebraska Medical Center, Omaha, Nebraska, United States

🇺🇸

Saint Francis Hospital / Bon Secours, Greenville, South Carolina, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 10 locations

Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies

First Posted Date
2013-06-07
Last Posted Date
2016-07-11
Lead Sponsor
SCRI Development Innovations, LLC
Target Recruit Count
48
Registration Number
NCT01871675
Locations
🇺🇸

Florida Cancer Specialists, Sarasota, Florida, United States

🇺🇸

Tennessee Oncology, PLLC, Nashville, Tennessee, United States

🇺🇸

Oklahoma University, Oklahoma City, Oklahoma, United States

and more 1 locations

BR in Patients With CLL With Comorbidities and/or Renal Dysfunction

First Posted Date
2013-04-16
Last Posted Date
2018-03-30
Lead Sponsor
Dartmouth-Hitchcock Medical Center
Target Recruit Count
8
Registration Number
NCT01832922
Locations
🇺🇸

Dartmouth-Hitchcock Medical Center, Norris Cotton Cancer Center, Lebanon, New Hampshire, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL

First Posted Date
2012-12-21
Last Posted Date
2023-06-27
Lead Sponsor
University of Wisconsin, Madison
Target Recruit Count
36
Registration Number
NCT01754857
Locations
🇺🇸

University of Wisconsin, Madison, Wisconsin, United States

Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma

Phase 1
Active, not recruiting
Conditions
Interventions
First Posted Date
2012-12-21
Last Posted Date
2024-02-20
Lead Sponsor
Cristina Gasparetto
Target Recruit Count
56
Registration Number
NCT01754402
Locations
🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

First Posted Date
2012-11-26
Last Posted Date
2018-11-16
Lead Sponsor
Gilead Sciences
Target Recruit Count
475
Registration Number
NCT01732926
Locations
🇨🇦

Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada

🇺🇸

Cancer Center of Kansas, Wichita, Kansas, United States

🇮🇹

Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi, Bologna, Italy

and more 138 locations

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

First Posted Date
2012-10-30
Last Posted Date
2024-06-11
Lead Sponsor
Seagen Inc.
Target Recruit Count
131
Registration Number
NCT01716806
Locations
🇺🇸

Wenatchee Valley Medical Center, Wenatchee, Washington, United States

🇺🇸

James Cancer Hospital / Ohio State University, Columbus, Ohio, United States

🇺🇸

Swedish Cancer Institute, Seattle, Washington, United States

and more 51 locations

Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma

Phase 2
Completed
Conditions
Interventions
First Posted Date
2012-10-04
Last Posted Date
2016-08-24
Lead Sponsor
Cantonal Hospital of St. Gallen
Target Recruit Count
50
Registration Number
NCT01701076
Locations
🇨🇭

Kantonsspital St. Gallen, St. Gallen, Switzerland

© Copyright 2024. All Rights Reserved by MedPath